Geisinger Medical Laboratories/Geisinger Proven Diagnostics Test Catalog

Order Display Name: Geisinger Epic Procedure Code Or ID CPT Code:  

ABL KINASE DOMAIN MUTATION IN CML, CELL-BASED

ORDERING INFORMATION:
Geisinger Epic Procedure Code: LAB1235         Geisinger Epic ID: 52865

SPECIMEN COLLECTION
Specimen type:
Whole blood or bone marrow aspirate
Preferred collection container:
Alternate Collection Container:
4 mL green/green-top (sodium heparin) tube
Specimen required:
5 mL whole blood; minimum 3 mL. 3 mL bone marrow aspirate; minimum 1 mL.
Special notes:
After collection of the sample, draw date and time, as well as sample type, must be written on the tube and included as requested information.

SPECIMEN PROCESSING
Specimen processing instructions:
**Ship sample immediately due to short sample stability of 72 hours.**If the stability of the sample cannot be determined, delay in result or cancellation of test may occur. 
Transport temperature:
Refrigerated (cold packs).
Specimen stability:
Room temperature: 72 hours. Refrigerated: 72 hours. Frozen: Unacceptable.
Do not reject specimens. Send to laboratory for screening.
Rejection criteria:
Grossly hemolysis • Lipemia • Frozen samples • Clotted whole blood samples • Clotted bone marrow samples

TEST DETAILS
Additional information:
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
CPT code(s):
81170
Note: The billing party has sole responsibility for CPT coding.  Any questions regarding coding should be directed to the payer being billed.  The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only.
Methodology:
Nested polymerase chain reaction
Real-time Polymerase Chain Reaction (PCR)
Sequencing
Synonyms:
Quest test code 16029, ABL Kinase, ABL Mutation, Cell-based,ABL Mutation
Clinical significance:
IMATINIB mesylate (ST1571;GLEEVEC) is a selective BCR-ABL kinase inhibitor, effective in the treatment of chronic Myelogenous Leukemia (CML). Most patients in chronic phase maintain durable responses; however, many in blast crisis fail to respond, or relapse quickly. ABL kinase domain mutations are the most commonly identified mechanism associated with relapse. The molecular monitoring in the first few months of therapy may play a crucial role in detecting patients at high risk of IMATINIB resistance. This ABL kinase mutation assay may detect drug-resistant mutations before clinical relapse and identify candidate suitable for alternative therapy.

Performing Locations

Quest Diagnostics

Technical Lead: Michael Weaver    
Frequency: Set up: Daily; Report available: 3-5 days.    
Performed stat? No
Locations  |    Search  |    Site Map |   Contact Us
©2000-2021 Geisinger Health System.   All rights reserved.